Ipsen S.A. (IPSEY)
IPSEY Stock Price Chart
Explore Ipsen S.A. interactive price chart. Choose custom timeframes to analyze IPSEY price movements and trends.
IPSEY Company Profile
Discover essential business fundamentals and corporate details for Ipsen S.A. (IPSEY) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
3 Aug 2012
Employees
5.36K
Website
https://www.ipsen.comCEO
David Loew
Description
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; Dysport for motor muscular disorders and medical aesthetics; NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, chronic renal failure, and GH deficiency in adults; and Increlex for growth failure in children and adolescents. The company also offers Smecta for chronic and acute diarrhea, and pain associated with functional bowel diseases; Forlax for constipation; Fortrans/Eziclen for bowel cleansing prior to endoscopy, X-ray examination, and colonic surgery; and Tanakan for cognitive disorders in adults, vertigo of vestibular origin and vestibular rehabilitation, and tinnitus. In addition, it provides Xermelo for the carcinoid syndrome; Cometriq for medullary thyroid cancer; Smebiocta/SmectaFlora Protect, a food supplement; SmectaGas, a medical device used in the symptomatic treatment of gas-related gastrointestinal disorders and relief of gas-related symptoms; and Etiasa for inflammatory bowel diseases. Further, the company offers other consumer healthcare products in the gastro-intestinal area, including Buscopan, Clin4000, Prontalgine, Suppositoria Glycerini, Mucothiol, Floractin, and Mucodyne. Ipsen S.A. has agreements with Debiopharm; Exelixis; Galderma; Blueprint Medicines; TerSera Therapeutics; Rhythm Pharmaceuticals; Teijin; Braintree Laboratories; Ethypharm; Schwabe; BAKX Therapeutics Inc.; and Exicure. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France.
IPSEY Financial Timeline
Browse a chronological timeline of Ipsen S.A. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 Feb 2026
Earnings released on 31 Jul 2025
EPS came in at $1.74 surpassing the estimated $1.63 by +6.75%, while revenue for the quarter reached $2.08B , missing expectations by -5.15%.
Dividend declared on 9 Jun 2025
A dividend of $0.26 per share was announced, adjusted to $0.26. The dividend was paid on 25 Jun 2025.
Earnings released on 13 Feb 2025
EPS came in at $0.35 , while revenue for the quarter reached $1.89B , beating expectations by +107.76%.
Earnings released on 23 Oct 2024
EPS came in at $0.75 falling short of the estimated $1.26 by -40.71%, while revenue for the quarter reached $1.88B , beating expectations by +2.57%.
Dividend declared on 21 May 2024
A dividend of $0.35 per share was announced, adjusted to $0.35. The dividend was paid on 14 Jun 2024.
Earnings released on 24 Apr 2024
EPS came in at $1.48 surpassing the estimated $1.42 by +4.23%, while revenue for the quarter reached $1.75B , missing expectations by -6.57%.
Earnings released on 30 Jun 2023
EPS came in at $0.64 falling short of the estimated $1.37 by -53.21%, while revenue for the quarter reached $1.68B , missing expectations by -0.19%.
Dividend declared on 19 May 2023
A dividend of $0.35 per share was announced, adjusted to $0.35. The dividend was paid on 21 Jun 2023.
Earnings released on 31 Dec 2022
EPS came in at $0.83 falling short of the estimated $1.34 by -38.43%, while revenue for the quarter reached $1.71B , missing expectations by -1.86%.
Earnings released on 30 Jun 2022
EPS came in at $1.24 surpassing the estimated $1.11 by +11.71%, while revenue for the quarter reached $1.50B , beating expectations by +7.53%.
Dividend declared on 27 May 2022
A dividend of $0.32 per share was announced, adjusted to $0.34. The dividend was paid on 9 Jun 2022.
Earnings released on 31 Dec 2021
EPS came in at $1.18 falling short of the estimated $1.19 by -0.84%, while revenue for the quarter reached $1.72B , beating expectations by +0.21%.
Earnings released on 30 Jun 2021
EPS came in at $1.08 falling short of the estimated $1.16 by -6.90%, while revenue for the quarter reached $1.60B , missing expectations by -1.50%.
Dividend declared on 25 May 2021
A dividend of $0.37 per share was announced, adjusted to $0.37. The dividend was paid on 9 Jun 2021.
Earnings released on 31 Dec 2020
EPS came in at $1.20 surpassing the estimated $1.06 by +13.21%, while revenue for the quarter reached $1.62B , missing expectations by -2.78%.
IPSEY Stock Performance
Access detailed IPSEY performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.